Please login to the form below

Not currently logged in
Email:
Password:

S-A's rifapentine granted Orphan Drug status

Sanofi-Aventis' tuberculosis drug, rifapentine, has been granted Orphan Drug status by the European Commission

Sanofi-Aventis' (S-A) tuberculosis (TB) drug, rifapentine, has been granted Orphan Drug status by the European Commission.

Rifapentine had already received a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) for offering a significant clinical benefit to TB patients by reducing the length of treatment.

The drug has been shown to offer a higher inhibitory activity against Mycobacterium TB and has a longer half-life than rifampin – the current standard medicine used in the treatment of TB.

As such, improved drug exposure for patients is expected, with the potential of superior efficacy.

Under its Orphan Drug classification, S-A will receive several benefits for the production of rifapentine, including scientific assistance in the product development phase of the drug; financial incentives such as fee reductions; and marketing authorisation, including 10-year marketing exclusivity in the EU.

"Rifapentine is currently one of the most promising drugs for the improvement of patient compliance, which is key to the success of tuberculosis treatment," said Robert Sebbag, vice president, Access to Medicines, S-A. "To avoid as much as possible the emergence of resistant strains, it is of utmost importance to simplify the treatment of non-resistant TB."

Orphan Drug status in Europe is granted to drugs used in the treatment of life threatening or chronically debilitating pathologies that affect no more than 5 in 10,000 people in the European Union. Medicines which, for economic reasons, would be unlikely to be developed without incentives, can also be given orphan drug status.

1st July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics